Intelligence Check: How Many Founding Investors Have Now Acquired Their Own Portfolio Companies in 2026?

Eli Lilly's acquisition of Ajax Therapeutics provides a notable example of a pharmaceutical company eventually buying a biotech it had backed at an earlier stage. Lilly participated in Ajax's $95 million Series C financing in 2024, and in April 2026 agreed to acquire the company for up to $2.3 billion, including milestone-based payments. Ajax was founded in 2019 and developed AJ1-11095, an experimental Type II JAK2 inhibitor for myelofibrosis and other myeloproliferative neoplasms.

Lilly Was More Than a Conventional Investor

The Ajax case is particularly interesting because Lilly had supported the company from its creation, making the eventual acquisition less like a completely new external M&A bet and more like an extension of an existing relationship. Lilly was among the investors in Ajax's 2024 financing, giving the company earlier visibility into the program before committing to the much larger acquisition. The deal illustrates why strategic investors can have an advantage when evaluating companies they have already followed through multiple development stages.

But Ajax Is Not the Only 2026 Example

The broader 2026 market shows that the "invest first, acquire later" model is not limited to Lilly. A particularly clear example is Nuvalent, which was founded in 2017 by Deerfield Management in collaboration with scientist Matthew Shair. Deerfield was the company's sole founding investor and funded its early development before Nuvalent eventually agreed to be acquired by GSK for $10.6 billion in June 2026. That makes Nuvalent a stronger example of a financial investor creating and funding a company before another strategic buyer ultimately acquires it.

Corporate Venture Capital Creates a Different Route

Other 2026 transactions show the same underlying principle from a different direction. Pfizer's venture portfolio, for example, includes Curevo Vaccine, which was acquired by Eli Lilly in 2026. This demonstrates the growing importance of corporate venture portfolios as pipelines of future strategic assets, even when the original investor is not the eventual buyer.

Founding Investors Can Capture More Than Financial Returns

The potential attraction of this model is clear: early investors obtain both financial exposure and detailed knowledge of the technology, management team and development program. If the asset later becomes strategically important, the investor—or its corporate parent—can potentially acquire it with considerably more information than a new bidder. Ajax's progression from early backing to a potential $2.3 billion exit illustrates the scale of value that can emerge between the initial investment stage and a strategic acquisition.

2026 Is Strengthening the Case for Strategic Backing

The pattern is becoming more relevant as pharmaceutical M&A accelerates. Biotech deal value reached approximately $84 billion in Q1 2026, nearly twice the level of the same period in 2025, as large pharmaceutical companies seek external assets to strengthen pipelines. Strategic investors therefore have an increasingly valuable position when they can identify promising companies early and maintain relationships until clinical data makes an acquisition attractive.

The Intelligence Takeaway

There is not yet a reliable single count for all 2026 cases where a founding or early corporate investor itself acquired the portfolio company, so Ajax should not be presented as proof of a specific industry-wide number. What can be established is a growing pattern of investor-backed biotech companies becoming acquisition targets: Ajax/Lilly and Deerfield/Nuvalent are particularly strong examples, while other corporate venture portfolios are producing valuable acquisition targets. The more important intelligence question is whether this model becomes a repeatable route for big pharma to identify and secure promising technologies before competitors do.